In conclusion, we have demonstrated that the IHC-based analysis of three markers, p53, EGFR and PDGFRA, allowed us to identify two GBM subtypes with prognostic significance in terms of overall survival and response to treatment. This evidence concerns the gene PDGFRA and glioblastoma.